[Comparison of the effect of a selective and a nonselective beta receptor blocker on the ischemic ST segment, lung...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Coronary artery disease (CAD) management often involves beta-blockers.
• Cardioselective beta-blockers offer potential advantages in pulmonary function.
• Understanding the effects of beta-blockers on blood glucose during exercise is crucial.

Purpose of the Study:

• Compare antihypertensive and anti-ischemic effects of betaxolol (cardioselective) versus nadolol (non-selective).
• Assess betaxolol's influence on pulmonary function compared to nadolol.
• Investigate the impact of beta-1 and beta-2 adrenergic blockade on blood glucose during ergometry.

Main Methods:

• Ten patients with CAD and stable angina underwent a randomized, double-blind, cross-over study.
• Drugs administered: placebo, betaxolol (20 mg), and nadolol (80 mg).
• Evaluations included bicycle ergometry, ST-segment depression monitoring, blood glucose levels, and pulmonary function tests.

Main Results:

• Both betaxolol and nadolol significantly reduced ST-segment depression compared to placebo.
• Reductions in ST-segment depression were observed at 4, 24, and 48 hours post-administration.
• Specific percentages for ST-segment depression reduction were provided for both drugs at different time points.

Conclusions:

• Betaxolol and nadolol demonstrate significant anti-ischemic effects in patients with CAD.
• The study provides data on the comparative efficacy and potential side effect profiles of these beta-blockers.
• Further research may clarify the impact on pulmonary function and glucose metabolism.